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Mu opioid receptors modulate a large number of physiological functions. They are
in particular involved in the control of pain perception and reward properties. They
are also the primary molecular target of opioid drugs and mediate their beneficial
analgesic effects, euphoric properties as well as negative side effects such as tolerance
and physical dependence. Importantly, mu opioid receptors can physically associate
with another receptor to form a novel entity called heteromer that exhibits specific
ligand binding, signaling, and trafficking properties. As reviewed here, in vivo physical
proximity has now been evidenced for several receptor pairs, subsequent impact of
heteromerization on native mu opioid receptor signaling and trafficking identified and
a link to behavioral changes established. Selective targeting of heteromers as a tool to
modulate mu opioid receptor activity is therefore attracting growing interest and raises
hopes for innovative therapeutic strategies.
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INTRODUCTION
The mu opioid (mu) receptor is a G protein-coupled receptor (GPCR) that neuromodulates several
physiological functions, in particular nociception (Kieffer and Evans, 2009). This receptor also
mediates the reinforcing properties of natural stimuli. In addition, mu receptors are the primary
molecular target of opioid drugs used in the clinic (e.g., morphine, codeine, oxycodone, fentanyl,
tramadol), and are responsible for their analgesic properties but also for the side effects associated
with their acute (e.g., respiratory depression, nausea, dizziness, sedation, constipation) (Kieffer,
1999) and chronic use (tolerance, hyperalgesia, and physical dependence) (Matthes et al., 1996;
Williams et al., 2013). Moreover, mu receptors mediate opioid rewarding and euphoric properties
that underlie their abuse potential (Matthes et al., 1996). The latter is at the root of the epidemic that
has developed in North America upon misuse and/or abuse of prescription opioid drugs after an
initial therapeutic use or in patients that self-medicate (Vowles et al., 2015). It underscores the need
for designing effective opioid analgesics devoid of side effects and has prompted considerable efforts
to better understand the molecular and cellular mechanisms underlying mu receptor activity. In
this context, functional consequences elicited by physical association of the mu receptor with
another GPCR attracted attention. Here, we review evidence of molecular, cellular, and behavioral
modulation induced by mu receptor heteromerization in native tissue.
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MU RECEPTOR HETEROMERS IN NATIVE
TISSUE
Heteromers involving the mu receptor have been extensively
studied in heterologous systems (Fujita et al., 2014a). Receptor
physical proximity has now been established in native tissue for
several receptor pairs using receptor co-immunoprecipitation,
co-localization by electron microscopy or in situ proximity
ligation assay (PLA), and/or disruption of physical contact by
an interfering peptide. The use of interfering peptide and/or
mice deficient for one receptor also significantly contributed to
demonstrate the specificity of the functional changes associated
with heteromer formation and to establish a causal link
with behavioral outputs. In native tissue, the mu receptor
heteromerizes with the delta opioid (delta) or kappa opioid
(kappa) receptors or with the non-opioid receptors ORL1,
cannabinoid CB1, galanin Gal1, adrenergic α2a, somatostatin
sst2, dopamine D1, chemokine CCR5, and vasopressin V1b.
Association between the mu receptor splice variant MOR1D and
the gastrin-releasing peptide receptor (GRPR) has also been
reported as well as mu physical proximity with the ion channel
NMDA (Table 1). Heteromerization with a Gαi/o coupled GPCR
is thus the most frequently reported to date but association with
the Gαq coupled GRPR and vasopressin V1B receptors or the Gαs
coupled dopamine D1 receptor indicates no specific requirement.
Additional heteromers likely exist in vivo since mu receptor
heteromerizes with serotonin 5HT1a (Cussac et al., 2012),
neuropeptide FF NPFF2 (Roumy et al., 2007), melanocortin MC3
(Rediger et al., 2009), neurokinin NK1 (Pfeiffer et al., 2003),
and possibly, dopamine D4 (Qian et al., 2018) receptors in co-
transfected cells, and neuronal co-localization with chemokine
CXCR4 (Patel et al., 2006; Heinisch et al., 2011), metabotropic
glutamate mGluR5 (Schröder et al., 2009) and serotonin 5HT2a
(Lopez-Gimenez et al., 2008), and dopamine D4 (Rivera et al.,
2017) receptors has been reported (see also http://www.gpcr-
hetnet.com for further information on the GPCR interaction
network, and interacting or non-interacting receptor pairs;
Borroto-Escuela et al., 2014).
Expression of native heteromers is dynamic. Chronic
morphine treatment enhances mu-delta heteromer density in
brain regions associated with the reward pathway (Gupta et al.,
2010). Concomitant increase in delta receptor localization at the
cell surface is observed and is mu receptor dependent (Gendron
et al., 2015; Ong et al., 2015; Erbs et al., 2016). Heteromers
form intracellularly in native tissue. In the mouse dorsal root
ganglia (DRG), mu and delta opioid receptors associate in the
endoplasmic reticulum (ER), which requires phosphorylation
of the delta receptor at threonine 161 by the cdk5 kinase
(Walwyn et al., 2009; Xie et al., 2009). Mu-delta density could
also be affected in other pathological conditions enhancing
delta receptor presence at the cell surface such as inflammatory
pain conditions (Cahill et al., 2003) or voluntary alcohol
consumption (van Rijn et al., 2012). In addition, expression of
mu-α2a heteromers in the nucleus of the solitary tract (NTS)
is dynamically regulated and increased in hypertensive rats
(Sun et al., 2015). In human peripheral blood mononuclear
cells (PBMC), the mu agonist DAMGO induced CCR5 receptor
synthesis through a TGFβ1 dependent mechanism (Happel et al.,
2008), suggesting a role for mu-CCR5 heteromers in HIV1 entry
in opiate abusers.
MODULATION OF G PROTEIN SIGNALING
IN NATIVE MU HETEROMERS
In SK-N-SH neuroblastoma cells co-expressing mu and delta
receptors, occupancy of the binding site of one receptor by
a non-signaling concentration of ligand increased binding
and Gα signaling of the other receptor (Gomes et al.,
2000, 2004, 2011). The nature of the first ligand did not
seem important since agonist, antagonist or inverse agonist
induced similar effects. Data therefore suggest that mu-delta
heteromerization induces cross-allosteric modulation with a
positive cooperativity promoted upon binding of the first ligand
(Figure 1). Accordingly, co-application of the delta antagonist
TIPPψ and mu agonist DAMGO or co-application of the
mu antagonist CTAP and delta agonists deltorphin II or
DPDPE increased hyperpolarization in a subset of neurons
in the ventral tegmental area (VTA) (Margolis et al., 2017).
Similarly, co-injection of subthreshold doses of the mu agonist
DAMGO and the delta agonist deltorphin II in the rostral
ventromedial medulla (RVM) of rats chronically treated with
morphine increased γ aminobutyric acid (GABA)ergic inhibition
through synergistic activation of the phospholipase A2 and cyclic
adenosine monophosphate (cAMP)/protein kinase A (PKA)
dependent pathways (Zhang and Pan, 2010). Moreover, mu-
delta preferential coupling to the pertussis toxin insensitive
Gαz subunit would not be desensitized by chronic morphine
administration in the rat striatum and hippocampus (George
et al., 2000; Kabli et al., 2014). Altogether, mu-delta positive
crosstalk reinforces the inhibition of neuronal activity.
In contrast, heteromers formed with a non-opioid receptor
appear to negatively modulate mu receptor G protein dependent
signaling (Figure 1). In the VTA, co-activation of mu-Gal1
heteromers by galanin and endomorphin 1 decreased
extracellular signal-regulated kinase ERK1/2, protein kinase
B (AKT), and cyclic AMP response element binding protein
(CREB) phosphorylation (Moreno et al., 2017). Accordingly,
galanin could not prevent dopamine release promoted by local
infusion of endomorphin 1 in the presence of an interfering
peptide that disrupt mu-Gal1 physical interaction (Moreno
et al., 2017). In addition, acute morphine administration
enhanced ERK1/2 activation in the nucleus accumbens (Nacc)
and amygdala of galanin knock-out mice compared to wild
type mice (Hawes et al., 2008). These data suggest a negative
crosstalk mediated by mu-Gal1 heteromers by which galanin
dampens mu receptor signaling. In addition, the mu antagonist
CTOP counteracted galanin induced ERK1/2, AKT and CREB
phosphorylation indicative of a cross-antagonism on Gal1
receptor signaling (Moreno et al., 2017).
In BE(2)-C neuroblastoma cells co-expressing mu and ORL1
receptors, pretreatment with nociceptin decreased DAMGO
potency and efficacy to inhibit adenylate cyclase (Mandyam
et al., 2002). This effect was abolished in HEK293 cells co-
transfected with receptor pairs unable to physically associate,
which supports heteromer specificity (Wang et al., 2005).
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TABLE 1 | Identification, properties, and functional outcome of native heteromers involving the mu opioid receptor.
Receptor
pair
In vivo physical proximity Specific properties of native heteromers
Tissue Technique References Ligand binding, receptor
signaling
and trafficking
Tissue Functional
outcome
References
MU HETEROMERS INVOLVING ASSOCIATION WITH A GI/O COUPLED RECEPTOR
Mu-delta Mouse brain, SC,
DRG
Co-IP
Disruptive peptide
Xie et al., 2009;
Kabli et al., 2013;
Erbs et al., 2015
Reciprocal positive crosstalk
upon co-activation with an
agonist, inverse agonist or
antagonist for the other
receptor (positive binding
cooperativity, increased Gα
signaling)
SKNSH, SC
VTA
Gomes et al.,
2000, 2004, 2011;
Margolis et al.,
2017
Increased by
morphine in
Selected brain
areas
Specific mu-delta
antibody
Gupta et al., 2010
Synergy upon co-activation in
chronic morphine treated rats
RVM Increased
analgesia
Zhang and Pan,
2010
Synergy upon co-activation in
chronic inflammatory condition
RVM Increased
analgesia
Sykes et al., 2007
Mu-delta surface expression DRG, SC Increased
analgesia
Walwyn et al.,
2009; Xie et al.,
2009
Disruption mu-delta heteromer SC, DRG Increased
Morphine
tolerance
Xie et al., 2009; He
et al., 2011
Mu-delta co-internalization
(UFP-512, CYM51010)
Striatum,
hippocampus
Anxiolytic, anti-
depressive,
analgesic,
decreased
morphine
tolerance and
dependence
Gomes et al.,
2013; Kabli et al.,
2013; Derouiche
et al., 2018
Increased β-arrestin signaling SKNSH cells Rozenfeld and
Devi, 2007
No uncoupling from Gz after
chronic morphine
Striatum,
hippocampus
Kabli et al., 2014
DAMGO induced delta recycling
to plasma membrane after
chronic morphine
DRG Ong et al., 2015
Mu-kappa Rat SC proestrous
females
Co-IP Chakrabarti et al.,
2010
Co-activation morphine/
dyn1-17 induced synergy
Increases
morphine
analgesia females
Chakrabarti et al.,
2010; Liu N. J.
et al., 2011
Mu-ORL1 DRG Co-IP Evans et al., 2010 Co-activation induced negative
crosstalk on ORL1 signaling
Neuroblastoma Nociception Mandyam et al.,
2002
Mu-CB1 Rat striatum Electron
microscopy
Rodriguez et al.,
2001
Co-activation induced
bidirectional negative crosstalk,
decreased mu agonist binding
Bidirectional cross antagonism
(Nacc)
SKNSH, striatum
Mu KO mice
CB1 KO mice
CB1 antagonist
Neuritogenesis
Social play
Vaysse et al.,
1987; Rios et al.,
2006
Manduca et al.,
2016
Mu-Gal1 Mouse VTA Disruptive peptide Moreno et al.,
2017
Co-activation induced negative
crosstalk
Cross-antagonism on Gal1
signaling
VTA Opioid drug
reward
Moreno et al.,
2017
Mu-α2a
adrenergic
Rat NTS
Increased
expression in
hypertensive rats
Co-IP
PLA
Sun et al., 2015 Opiate induced increased
co-expression
Co-activation induced negative
crosstalk
receptor co-internalization
RVM
Primary SC
neurons
DRG
Hypertension Sun et al., 2015
Jordan et al., 2003
Tan et al., 2009
(Continued)
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TABLE 1 | Continued
Receptor
pair
In vivo physical proximity Specific properties of native heteromers
Tissue Technique References Ligand binding, receptor
signaling
and trafficking
Tissue Functional
outcome
References
Mu-sst2 Human pancreatic
cancer cells
Co-IP
FCS
Jorand et al., 2016 Co-activation increased
β-arrestin signaling, decreased
EMT
Pancreatic cancer
cell line
Increased cancer
metastatis
Jorand et al., 2016
Mu-CCR5 Human and
monkey PBMC
Co-IP Suzuki et al., 2002 Negative crosstalk
Cross-antagonism
CCR5 KO mice
CCR5 antagonist
Decreased
nociception
HIV infection
Lee et al., 2013
Szabo et al., 2002
MU HETEROMERS INVOLVING ASSOCIATION WITH A Gs COUPLED RECEPTOR
Mu-D1 Mouse striatum
mPFC
Co-IP
Co-localization
Tao et al., 2017 Cross-antagonism D1 KO mice
D1 antagonist
Opiate locomotor
sensitization
Tao et al., 2017
MU HETEROMERS INVOLVING ASSOCIATION WITH A Gq COUPLED RECEPTOR
Mu-V1b Mouse RVM ISH
Truncated V1b
receptor
Koshimizu et al.,
2018
Increased β-arrestin signaling RVM Enhanced
morphine
tolerance
Koshimizu et al.,
2018
MOR1D-
GRPR
Mouse SC Co-IP
Disruptive peptide
Liu X. Y. et al.,
2011
Positive crosstalk on GRPR
signaling
SC Morphine induced
itch
Liu X. Y. et al.,
2011
MU HETEROMERS INVOLVING ASSOCIATION WITH AN ION CHANNEL
Mu-NMDA Mouse PAG Co-IP Rodríguez-Muñoz
et al., 2012
Positive crosstalk on mu
receptor and negative crosstalk
on NMDA CAMKII pathway
PAG Decreased
morphine
analgesia and
increase morphine
tolerance
Rodríguez-Muñoz
et al., 2012
Co-IP, Co-immunoprecipitation; DRG, Dorsal Root Ganglia; PAG, Periaqueductal Gray; PBMC, peripheral blood mononuclear cells; PLA, Proximity Ligation Assay; RVM, Rostral Ventral
Medulla; SC, Spinal Cord; VTA, Ventral Tegmental Area.
Additional examples of negative crosstalk on mu receptor
signaling can be linked to heteromerization. Co-activation of mu
and cannabinoid CB1 receptors by the mu agonist morphine
and a non-signaling dose of the CB1 agonist WIN 55,212-
2 decreased [35S]guanosine 5′-[γ-thio]triphosphate (GTPγS)
binding and ERK1/2 signaling in SK-N-SH neuroblastoma
cells (Rios et al., 2006) and 19-tetrahydrocannabinol (THC)
allosterically decreased dihydromorphine binding at the mu
receptor in rat striatal membranes (Vaysse et al., 1987).
Similarly, co-activation of mu and adrenergic α2a receptors
decreased ERK1/2 phosphorylation in primary spinal cord
neurons (Jordan et al., 2003). Also, the chemokine CCL5 induced
phosphorylation of the mu receptor in human PBMC indicating
cross-desensitization (Szabo et al., 2002). Finally, the dopamine
D1 antagonist SCH233390 decreased G protein activation and
ERK1/2 phosphorylation induced by the mu agonist DAMGO
in mouse striatal membrane from wild type but not mice
deficient for the D1 receptor (Tao et al., 2017). Activation of
mu-NMDA heteromers by N-methyl-D-aspartate (NMDA) in
the periaqueductal gray (PAG) also negatively regulated mu
receptor activity by promoting PKA-dependent dissociation of
the heteromer and subsequent mu receptor phosphorylation.
This in turn promoted G protein uncoupling and receptor
desensitization (Rodríguez-Muñoz et al., 2012).
Interestingly, constitutive activity has been reported for delta
opioid (Costa and Herz, 1989), kappa opioid (Sirohi andWalker,
2015), ORL1 (Beedle et al., 2004), cannabinoid CB1 (Fioravanti
et al., 2008), adrenergic α2a (Pauwels et al., 2000), and mu opioid
receptors (Wang et al., 2004). Since heteromers involving the mu
receptor form in the ER in a ligand independentmanner, receptor
constitutive activity could represent an important determinant
of the allosteric modulation and could contribute to the basal
homeostasis of the cell in the absence of receptor stimulation.
The release of endogenous peptides would however further
modulate their functional impact because these receptors can still
be activated by agonists (Canals and Milligan, 2008).
ACTIVATION OF β-ARRESTIN SIGNALING
IN NATIVE MU HETEROMERS
In SK-N-SH neuroblastoma cells co-expressing mu and delta
receptors, activation by the mu agonist DAMGO changed the
spatio-temporal profile of ERK1/2 phosphorylation (Rozenfeld
and Devi, 2007) (Figure 1). This was abolished in the presence
of a β-arrestin 2 small interfering ribonucleic acid (siRNA)
or in the presence of the delta selective antagonist TIPPψ
(Rozenfeld and Devi, 2007) suggesting that activation of
heteromers involving the mu receptor can promote β-arrestin
dependent signaling. Mice deficient for β-arrestin 2 developed
less tolerance to morphine (Bohn et al., 2002), data thus
suggest that the recruitment of the β-arrestin pathway by mu
heteromers contributes to morphine tolerance. This hypothesis
is also supported by the observation that tolerance to morphine
develops more slowly in mice deficient for the vasopressin
V1B receptor or in the presence of a V1B selective antagonist
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FIGURE 1 | Impact of heteromerization on mu opioid receptor signaling and trafficking. Heteromerization can take place in the endoplasmic reticulum. Association
with another opioid receptor positively modulates mu opioid receptor G protein-dependent signaling whereas association with a non-opioid receptor negatively
regulates it. Heteromerization also favors the recruitment the β-arrrestin dependent pathway upon internalization in the endosomal compartments. Native receptor
pairs for which information is available are indicated.
(Koshimizu et al., 2018). In the mouse RVM, vasopressin V1B
receptors constitutively associate with β-arrestin 2 through a
leucine rich motif present in the V1B C-terminus (Koshimizu
et al., 2018). This suggests that physical association with the
V1B receptor facilitates the recruitment of the β-arrestin pathway
by the mu receptor, and contributes to the development of
morphine tolerance. Accordingly, removal by genome editing
with the clustered regularly interspaced short palindromic
repeats-CRISPR associated protein 9 (CRISPR-Cas9) system
of the leucine rich motif responsible for the receptor V1B-β-
arrestin interaction increased morphine-induced analgesia and
reduced adenylate cyclase supersensitization and morphine-
induced tolerance and physical dependence (Koshimizu et al.,
2018).
Of note, co-activation of mu and somatostatin sst2 receptors
by dermorphin and L-054,264 in pancreatic cancer lines similarly
altered the spatio-temporal profile of ERK1/2 phosphorylation,
potentiating the epithelial to mesenchymal transition (Jorand
et al., 2016).
RECEPTOR CO-INTERNALIZATION IN
NATIVE MU HETEROMERS
Co-internalization of endogenous heteromers is less documented
largely due to the lack of appropriate tools (Figure 1).
Receptor internalization contributes to desensitize G protein
dependent signaling and favors β-arrestin dependent signaling
(Calebiro et al., 2010). Accordingly, co-internalization of mu
and adrenergic α2a receptors was dependent on β-arrestin 2
recruitment and mitogen-activated protein kinase (MAPK) p38
activation in the mouse DRGs (Tan et al., 2009).
Mu-delta co-internalization was observed following
activation by the mu-delta biased agonist CYM51010 in
primary hippocampal neurons from fluorescent double knock-in
mice (Derouiche et al., 2018) but could not be detected in
the spinal cord following SNC80 application (Wang et al.,
2018). Since SNC80 promoted mu-delta co-internalization in
co-transfected HEK293 cells (He et al., 2011), this observation
highlights the influence of the cellular environment.
MU HETEROMERS MODULATE
NOCICEPTION, MORPHINE ANALGESIA
AND TOLERANCE
Several observations support the implication of mu heteromers
in the control of the nociceptive threshold. The lower response
to inflammatory or chemical stimuli in CCR5 knock-out mice
or upon injection of a CCR5 antagonist indicate that mu-
CCR5 heteromers contribute to dampen the basal nociceptive
threshold by exerting a negative crosstalk on mu receptor
signaling (Lee et al., 2013). Mapping mu and delta receptors
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in the central and peripheral nervous systems using double
fluorescent knock-in mice revealed mu-delta co-expression in
discrete neuronal populations located in networks involved in
the perception and processing of nociceptive stimuli (Erbs et al.,
2015). Accordingly, disrupting mu-delta physical interaction
with an interfering peptide in naïve mice increased morphine-
induced thermal analgesia (He et al., 2011). In rats chronically
treated with morphine or with persistent inflammatory pain, co-
administration of low doses of mu and delta agonists in the
RVM enhanced mechanical and thermal analgesia (Sykes et al.,
2007; Zhang and Pan, 2010). Since delta receptor expression is
increased in both pathological conditions (Cahill et al., 2003;
Gendron et al., 2015; Ong et al., 2015; Erbs et al., 2016), this
synergistic effect can be explained by the positive crosstalk at
mu-delta heteromer elicited by receptor co-activation (Gomes
et al., 2000, 2004, 2011). Similarly, co-activation bymorphine and
the subsequently released dynorphin 1–17 acted synergistically
at mu-kappa heteromers to increase spinal morphine analgesia
(Chakrabarti et al., 2010). However, this effect is sex-dependent
and more pronounced in proestrous female mice where mu-
kappa heteromers are most abundant (Chakrabarti et al., 2010;
Liu N. J. et al., 2011).
Activation of mu-delta heteromers by the mu agonist
DAMGO (Rozenfeld and Devi, 2007) or co-activation of mu-
V1b heteromers by vasopressin and morphine (Koshimizu
et al., 2018) increased β-arrestin 2 recruitment and signaling.
Importantly, this pathway participates to the development of
morphine tolerance (Bohn et al., 2000), which suggests a
contribution frommu heteromers. Accordingly, disruption of the
physical contact between the mu and delta opioid receptors (Xie
et al., 2009; He et al., 2011) or between the mu and vasopressin
V1b receptors (Koshimizu et al., 2018) decreased morphine
tolerance. In addition, activation of mu-NMDA heteromers in
the PAG reduces morphine efficacy through a dual mechanism.
Indeed, stimulation by NMDA decreases the analgesic effect
of morphine by exerting a negative crosstalk on mu signaling
whereas morphine binding to the mu receptor potentiates the
NMDA-Ca2+/calmodulin-dependent protein kinase (CAMKII)
pathway and contributes to morphine tolerance (Rodríguez-
Muñoz et al., 2012).
Other roles formu heteromers includemorphine-induced itch
generated by cross-activation of the GRPR signaling in MORD1-
GRPR heteromers (Liu X. Y. et al., 2011). Moreover, mu-α2a, mu-
CB1, ormu-ORL1 heteromers very likely represent additional key
players since all four receptors modulate nociception but, to date,
a direct link to heteromerization with the mu receptor is still
lacking.
MU HETEROMERS MODULATE REWARD
PROCESSING AND ADDICTION TO OPIOID
DRUGS
Modulation of mu receptor signaling by heteromer formation
in the mesocorticolimbic pathway is bound to have a profound
impact on the rewarding properties of opioid drugs and
natural stimuli. Accordingly, galanin-dependent dampening of
opiate reinforcing and rewarding properties was abolished upon
disruption of mu-Gal1 heteromers in the VTA (Moreno et al.,
2017) or in galanin knock-out mice (Hawes et al., 2008).
Also, chronic morphine treatment increased mu-delta heteromer
expression in several brain regions including the VTA and Nacc
(Gupta et al., 2010). Therefore, the positive cross talk at mu-
delta heteromers observed in a subset of VTA neurons could
contribute to increased dopamine release in the Nacc and opiate
reinforcing properties (Margolis et al., 2017).
Also, systemic injection of the endocannabinoid 2-
arachidonoyl (2-AG) hydrolysis inhibitor JZL184 increased
the concentration of the endogenous ligand and enhanced social
play behavior in adolescent rodents (Manduca et al., 2016).
This effect was blocked by infusing the mu antagonist CTAP
in the Nacc and was absent in mu receptor knock-out mice
(Manduca et al., 2016). Reciprocally, systemic injection of the
mu agonist morphine increased social play and was abolished
by the CB1 antagonist SR1417-16 or in CB1 receptor knock-out
mice (Manduca et al., 2016). This bidirectional cross-antagonism
suggests that mu-CB1 heteromers in the Nacc modulate the
strong rewarding value of social play.
Mu receptors are also involved in other aspects of opiate
addiction such as locomotor sensitization and could achieve their
modulatory control through heteromerization with dopamine
D1 receptors. Indeed, opiate hyperlocomotion and locomotor
sensitization were abolished in dopamine D1 receptor in knock-
out mice or following local injection of the D1 antagonist
SCH23390 in the Nacc (Tao et al., 2017).
MU HETEROMERS MODULATE ANXIETY
AND DEPRESSION
Pharmacological and knock-out based studies linked an
anxiogenic and depressant phenotype to mu receptor activation
and, on the opposite, associated an anxiolytic and antidepressant
phenotype with delta receptor activation (Lutz et al., 2014).
Systemic administration or local micro-infusion in the Nacc
of the delta agonist UFP512 promoted anxiolytic- and anti-
depressant-like activity (Vergura et al., 2008; Kabli et al., 2013).
These effects were abolished by pretreatment with the mu
antagonist CTOP or the delta antagonist naltrindole or following
disruption of mu-delta physical contact in the Nacc (Kabli et al.,
2013). These data therefore suggest that accumbal mu-delta
heteromers participate to the modulation of anxio-depressive
states.
MU HETEROMERS MODULATE
METABOLIC DISORDERS
Mu receptors are known to control autonomous functions.
Higher levels of mu-α2a heteromers in the NTS were correlated
with increased blood pressure in hypertensive rats (Sun
et al., 2015). In normotensive rats, mu-α2a heteromerization
induced by the mu agonist DAMGO was paralleled by
increased blood pressure. Treatment with the mu antagonist
CTAP antagonized DAMGO changes in normotensive rats
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and reduced mu-α2a heteromerization and blood pressure in
hypertensive rats (Sun et al., 2015). Thus, activation of the
mu receptor by endogenous opioid peptides dampens the
activity of the α2a adrenergic receptors thereby potentiating
hypertension.
Interactions between mu and somatostatin receptors have
been postulated to influence tumor cell growth (Hatzoglou et al.,
2005). Recently, mu-sst2 heteromers were identified in pancreatic
cancer lines and in tissue from patients with pancreatic ductal
adenocarcinoma. Co-activation of the receptors initiated the
epithelial to mesenchymal transition, which is associated with
increased metastatic potential (Jorand et al., 2016).
MU HETEROMERS AS A NOVEL
THERAPEUTIC TARGET
The bivalent ligand MDAN-21 composed of the mu agonist
oxymorphone and the delta antagonist naltrindole tethered
by a 21 amino acid long linker was developed to selectively
target mu-delta heteromers (Daniels et al., 2005). The length
of the linker was designed to enable simultaneous binding of
the two ligand moieties to the orthosteric binding pockets of
two GPCRs in physical contact. MDAN-21 induced analgesia
with low tolerance, low physical dependence and no reinforcing
properties (Daniels et al., 2005; Lenard et al., 2007; Aceto et al.,
2012) providing a proof of concept that selective targeting of mu-
delta heteromers may represent a valid therapeutic strategy, in
particular for patients on opiate maintenance treatment.
More recently, the bivalent ligand MCC22 linking the mu
agonist oxymorphone to the CCR5 antagonist TAK220 has
been proposed to inhibit inflammatory and neuropathic pain by
targeting mu-CCR5 heteromers (Akgün et al., 2015). This is in
line with the enhanced nociception observed in CCR5 receptor
knock-out mice or in the presence of a CCR5 antagonist (Lee
et al., 2013).
A major limitation to the therapeutic use of bivalent ligands
is their poor capacity to cross the blood brain barrier (Le
Naour et al., 2013; Jörg et al., 2015). Therefore, monovalent
bifunctional ligands that would selectively target mu heteromers
have been developed (Schiller, 2010; Günther et al., 2018).
Eluxadoline is a mixed mu agonist delta antagonist recently been
approved by the FDA for the treatment of the irritable bowel
syndrome (FDA application N◦206940). Arguments in favor of
binding to mu-delta heteromers include lower efficacy in mice
deficient for the delta receptor and reduced signaling in the
presence of mu-delta selective antibodies (Fujita et al., 2014b).
Eluxadoline thus represents the first drug on the market designed
to target heteromers. In preclinical models, other ligands further
support preferential activation of mu heteromers as a valuable
therapeutic approach. The mu-delta biased agonist CYM51010
induced potent thermal analgesia comparable to morphine but
less tolerance and physical dependence (Gomes et al., 2013) and
the mu-kappa agonist NNTA produced strong analgesia devoid
of tolerance, physical dependence, or reinforcing properties upon
intrathecal injection in mice (Yekkirala et al., 2011).
CONCLUSION
Our current appreciation of the role of mu heteromer is still
in its infancy and their contribution to mu receptor-dependent
behavior likely underestimated. So far, physical proximity has
only been validated for a limited number of receptor pairs in vivo
and their functional interactions addressed in a handful of tissue
or brain areas. Moreover, heteromer expression is dynamically
regulated depending on physiopathological conditions. No doubt
that both novel functions and receptor pairs will be uncovered in
the future, which further emphasizes their potential as innovative
therapeutic targets.
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